Biologic therapy in Sjogren's syndrome

Sjogren's syndrome (SS) is a chronic autoimmune disease with complex and diverse clinical manifestations. It is characterized by lymphocyte infiltration of exocrine glands such as the salivary gland and lacrimal gland leading to insufficient secretion of the gland, manifested as dry mouth and dry eyes. In addition, it can involve extraglandular organs and cause systemic damage. The pathogenesis of SS is still unclear. At present, symptomatic treatment is the mainstay and there is a lack of effective therapy. With the development of molecular pathways underlying the pathogenesis of SS, more and more novel biological agents are used to treat SS. We summarized and analyzed the existing evidences on the efficacy of biological treatment of SS and their targets. Analysis of the efficacy of biological therapy and improvement of treatment strategies can help to give full play to its therapeutic advantages.

Automated summary

Sjogren's syndrome is a chronic autoimmune disease characterized by dry mouth, dry eyes, and potential systemic damage. Current treatment mainly focuses on symptomatic relief, but the use of biological agents is becoming more prominent in improving therapeutic outcomes. Further research and analysis of biological therapy efficacy can help optimize treatment strategies for SS.